John Goldfinch
MBA, CRM, US Clinical Lead & CEO - TILT Biotherapeutics LLC
U.S. Clinical Lead, John Goldfinch, brings more than 18 years’ experience in oncology clinical development and project management. In his previous role at Nirogy Therapeutics, he was Senior Director of Project Management, where he managed the lead compound through preclinical and IND development.
Prior to joining Nirogy, John spent 10 years at Athenex, where he served increasing role of responsibility, lastly as the Director of Clinical Operations for the company. John was responsible for managing the global development program of the company’s lead candidate through FDA submission.
He started his career as a Network Project Coordinator at Roswell Park Cancer Center where he was responsible for managing external clinical trials.
At TILT, John is responsible for advancing TILT’s US clinical program of phase I and II clinical trials, maintaining and initiating contacts with the clinical trial sites, managing CROs, and participating to the regulatory interactions. Since 2025, John also directs TILT’s fully owned U.S. affliliate as the CEO of TILT Biotherapeutics LLC.
John holds an MBA in Healthcare Management from the University of Phoenix and a Post Graduate Certificate in Clinical Research Management from Duke University.
